2020 Compounding Omnicell 
Omnicell
SEPTEMBER 5, 2022
Randall Lipps Chairman, President, CEO, and Founder, Omnicell Today, I was excited to join thousands of registrants representing pharmacy, nursing, informatics, and healthcare leaders for the launch of Omnicell Illuminate 2020 , one of the year’s biggest digital events dedicated to technology-driven medication management.
Omnicell
SEPTEMBER 5, 2022
Terri Albarano, PharmD Director, Autonomous Pharmacy, Omnicell Sterile compounding safety is one of the biggest challenges for the pharmacy supply chain. Health systems are expected to compound IV preparations with increasingly complex regulations, rising drug costs, and supply disruptions. Injectable medications cause 1.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Omnicell
SEPTEMBER 5, 2022
David Webster Director of Acute Care Pharmacy Operations, University of Rochester Medical Center Sterile compounding is one of the most high risk, high cost areas of medication management. Manual compounding is fraught with error, studies indicating 1 in 10 IVs are not prepared according to guidelines.
Omnicell
SEPTEMBER 5, 2022
Joy Somogyi Senior Director of Product Marketing and Development, Omnicell With two million people suffering from opioid addiction and 115 people dying from an opioid overdose every day in the U.S., the opioid crisis is one of the major challenges healthcare is facing, specifically for pharmacies currently managing medication diversion.
Omnicell
SEPTEMBER 5, 2022
Mark Neuenschwander Founding Director, THRIVCoalition.org Seminal research from 1997 on IV compounding discovered that 9 percent of manually compounded sterile preparations had incorrect ingredients and/or volumes. Worst yet, 74% of all respondents were aware of at least one pharmacy compounding error in the last 12 months.
Expert insights. Personalized for you.
52 
Let's personalize your content